Amphiphilic peptide conjugation affords a significant increase in sensitivity with protein quantification by electrospray-ionization mass spectrometry. This has been demonstrated here for human growth hormone in serum using N-(3-iodopropyl)-N, N, N-dimethyloctylammonium iodide (IPDOA-iodide) as derivatizing reagent. The signal enhancement achieved in comparison to the method without derivatization enables extension of the applicable concentration range down to the very low concentrations as encountered with clinical glucose suppression tests for patients with acromegaly. The method has been validated using a set of serum samples spiked with known amounts of recombinant 22 kDa growth hormone in the range of 0.48 to 7.65 µg/L. The coefficient of variation (CV) calculated, based on the deviation of results from the expected concentrations, was 3.5% and the limit of quantification (LoQ) was determined
Introduction
The reliability of data regarding growth hormone (GH) levels in human serum is crucial for diagnosis and decision-making in the treatment of several diseases, most prominently GH deficiency, gigantism and acromegaly. Poor comparability between testing laboratories has motivated the development of isotope dilution mass spectrometry (IDMS) as an alternative to immunoassays. 1 The method offers an option to the acquisition of GH target values for serum materials as currently used in ring trials 2 for quality assurance of clinical testing laboratories, where concentrations typically are well above 5 µg/L.
However, for the method to be of practical use with real patient samples, further improvement in sensitivity was required. GH excretion is mainly pulsatile. High levels of the hormone are only seen immediately after the pulse, whereas concentrations are much lower in the nadir and nonsecreting state. For a diagnosis of acromegaly, basal GH has to be measured, which should be found in a wide concentration range higher than 1 µg/L in case of acromegaly, or can be excluded by levels of less than 0.4 µg/L in healthy individuals. 3 In borderline cases, the suppression of GH during oral glucose tolerance tests is used to distinguish between healthy subjects and patients with active acromegaly. Upper cutoff limits have been reported, which vary between about 1-3 µg/L depending on the assay used. [4] [5] [6] IDMS offers an approach to a SI-traceable and antibody-independent redefinition of the decision limit. It is demonstrated here that the improvement of the signal-to-noise ratio needed to further extend the accessible concentration range down to 1 µg/L, and less, can be gained by a chemical conjugation of the tryptic signature peptide used for quantification. N-(3-iodopropyl)-N, N, N-dimethyloctylammonium iodide (IPDOA-iodide) has been synthesized for this purpose and used as a derivatizing reagent in the present study.
Experimental Section
Materials. GH Reference Solution. The preparation of this in-house reference material has been described in a previous report. 7 It is a solution of recombinant 22 kDa GH (Swiss-Prot P01241-1, A26M, aa26-217) in acetonitrile/water (1:1, v/v) which had been obtained from ProSpec-Tany TechnoGene (Rehovot, Israel). GH concentration is 30.8 nmol/g (686 µg/g).
Isotopically Labeled GH. Growth hormone, 22 kDa isoform, U-15 N labeled, 98%, was kindly provided by Jens Breinholt, Novo Nordisk, Måløv, Denmark. This will be referred to as GH*.
A solution of GH* in acetonitrile/water (1:1, v/v) was prepared as stock to provide the internal standards needed for IDMS-analysis. The concentration of this solution was determined by the comparison of mass spectrometric signals of tryptic GH* fragments to those of GH in-house standard which had been added in a known amount. GH* concentration was found to be 27.3 nmol/g (611 µg/g) with the stock solution.
GH-Fragment T6. Peptide YSFLQNPQTSLCFSESIPTPSNR, corresponding to Swiss-Prot P01241-1, aa68-90, had been obtained by custom synthesis from Thermo Fisher (Ulm, Germany).
A solution of T6 (107 nmol/g, i.e., 280 µg/g, in aqua) was prepared from this and used as stock solution for the experiments within this study.
GH-Depleted Serum. The frozen human serum material was from SunnyLab (SCIPAC), Sittingbourne, UK. It is pooled serum. The product code is SF220-2, batch number 172-156. GH level according to the supplier's certificate is less than 0.1 µg/L.
Calibrators. Calibrators were prepared by spiking the appropriate amount of GH reference solution into 500 µL of depleted serum. GH-Quantification Method. Setting up Sample and Calibrator. 500 µL of serum sample were used for each run. With each sample, a calibrator was prepared at a GH concentration, matching as closely as possible the concentration expected in that sample. Then both sample and calibrator were spiked with equal amounts of GH* (isotopically labeled GH). The amount of GH* also was chosen so as to match the concentration of GH in both sample and calibrator.
Sample Pretreatment. After spike-equilibration, sample and calibrator were subjected to tryptic proteolysis as previously described. 1 DTT and water/TFA were added at the end as described, but the reaction of the mixture with iodoacetamide was left out.
Extraction of T6 (T6*) by RP-and SCX-Liquid Chromatography. Fragments T6 (as formed from GH) and T6* (from GH*) were isolated by reversed phase (RP) chromatography followed by strong-cation exchange (SCX-) chromatography using a Jupiter-RP C18 column (10×250 mm, 300 Å) and a Luna-SCX column (10×250 mm, 100 Å, 5 µm) Phenomenex, Torrance, CA, USA. The most abundant ion observed for IPDOA-conjugated T6 was [(IPDOA-T6)+2H] 3+ under electrospray conditions which had been optimized for signal abundance. The CID-fragmentation spectrum of this ion is shown in Figure 3A .
By the masses of y 11 (the last fragment in the series not yet containing cysteine) and the first fragment that includes cysteine (y 12 ), even though the signals are of low abundance, it is evident that IPDOA has conjugated T6 at cysteine. Also, ions in the y-series that correspond to cysteinecontaining fragment ions (namely y 17 , y 18 , y 19 ) are doubly charged, while the shorter ones (most prominently y 6 ) are singly charged. This is in striking contrast to the behavior of carbamidomethylated T6 (CAM-T6, Figure 3B ), which produces exclusively singly charged fragment ions. Obviously, a permanent positive charge is located at the IPDOA-conjugated cysteine, as expected.
Matrix Effect on Signal Intensities of Carbamidomethylated vs. IPDOA-Conjugated T6-
Peptide. This experiment was conducted to characterize the influence of matrix-load on the mass (CAM-T6). Conditions were chosen to be representative for the composition of a sample extract after chromatographic clean-up according to the GH-quantification method given in this paper.
To this end, GH-depleted serum (500 µL) was subjected to the extraction procedure by RP-LC and subsequent SCX-chromatography as described in the Experimental Section. In particular, the fractions that normally would contain T6 (T6*) were collected (T6* is referring to the isotopically labeled T6). The "cleaned-up" serum material obtained this way would be used to mimic remaining matrix impurities still present at this stage of the analysis procedure in spite of the clean-up. In GH-Quantification Method. The entire method can be summerized as follows:
1. Spike the serum sample (500 µL) with U-15 N labeled GH, (GH*). The same with the respective calibrator (GH-depleted serum plus a known amount of GH). With both:
2. Proteolyze (trypsin, 37 • C). Lyophilize. Collect with water (2% trifluoroacetic acid).
3. Extract T6, T6* by (1) C18-Reversed phase liquid chromatography (RP-LC) followed by A series of samples (depleted serum spiked with known amounts of 22 kDa GH) was used for the validation of this method. The results are compiled in Table 1 . As an example for illustration, the LC/MS-MS signal obtained for the 0.95 µg/L sample is shown in Figure 5A , the corresponding result with the T6-CAM method, for comparison, in Figure 5B . In order to check if the method is producing useful results with real samples too, a set of native sera from healthy donors at basis-levels of GH concentration were analysed in duplicate. Results (µg/L) were: 0.69±0.04; 0.82±0.03;
1.50±0.05; 1.00±0.06. LC/MS-MS responses for two of these sera are shown in Figure 5 , (C) and (D). substrate), [13] [14] [15] [16] [17] [18] [19] increasing basicity so as to promote protonation in solution, 20 or on introducing a permanent positive charge in addition to non-polar moieties. 21, 22 IPDOA-iodide ( Figure 1 ) has been designed as a new reagent featuring a quaternary ammonium site next to a longer aliphatic moiety, which lends the molecule both of the properties believed to be necessary for optimal promotion of ion formation. Unlike previous work using NHS-esters of carboxylic acids as reagents,
IPDOA-iodide only reacts with peptides containing cysteine. These are then selectively enhanced, while excluding the rest of the peptides ( Figure 6 ). This was expected to be an advantage over reagents uniformly modifying all peptides, particularly so if working with complex matrices as serum. On the other hand, of course, the set of tryptic signature peptides available for quantification of an analyte protein is correspondingly confined in this way. 23, 24 this may lead to the conclusion that IPDOA-conjugated T6 on average is outcompeting the background of serum derived peptides for the excess charge on the ESI-droplet, whereas it is happening the other way round with CAM-T6. The advantage of using IPDOA-iodide is illustrated in Figure 5 . For a serum sample at a GH concentration of 0.95 µg/L, which is less than the limit of quantification determined for the CAM-based method (1.7 µg/L), a signal of well-acceptable signal-to-noise ratio is still obtained for IPDOA-T6 (A), while the signal for CAM-T6
(B) can scarcely be used for quantification.
Absolute Quantification of Growth Hormone by Isotope Dilution Mass Spectrometry.
Strategies for extracting cleavage fragments of interest from body fluids for subsequent analysis by IDMS have been reviewed recently by Halquist & Karnes. 25 In principle, it appears reasonable and easier to first isolate or enrich as much as possible the targeted protein itself (plus isotopically labeled protein used as internal standard) in order to reduce complexity prior to tryptic proteolysis and LC/MS-MS. In this study, however, the alternative of first completely proteolyzing the serum sample and then extracting the signature peptides from the mixture, proved simple and reproducible according to the developed protocol. In a previous investigation (development of the CAM-T6 based method) 1 it was found that the extraction of the peptide from the proteolysate by reversed phase chromatography (RP-LC) followed by further clean-up using strong cationexchange (SCX-) chromatography would yield better results than RP-LC alone, in terms of signalto-noise ratio. This was not changed in designing the present method. However, deviating from the original method, where conjugation by iodoacetamide is done directly after proteolysis, with the IPDOA-T6 protocol, the (reduced, but non derivatized) T6 (T6*) fraction is first isolated from the proteolysate and only then IPDOA-conjugated. This is owing to the fact that, IPDOA-iodide, otherwise present in excess as an ion pairing agent, would be severely compromising separation by RP-LC as well as by SCX-chromatography. For the same reason, after IPDOA-conjugation of T6(T6*) an additional RP-LC step was introduced in order to cut away excess of reagent prior to analytical LC/MS-MS.
The data compiled in Table 1 Unlike previous feasibility studies, which had demonstrated the detectability of plasma GH either at concentration levels far above physiological (≥ 1000 µg/L) 26 or with model samples of unrealistically diluted plasma background, 27 the method described here is applicable to native patient samples for diagnostic purposes.
Conclusion
Absolute quantification by LC/ESI-IDMS, owing to a reliability inherent to the measurement prin- here, using the example of growth hormone measurement, that selective conjugation of the analyte makes a contribution to improving the sensitivity of mass spectrometric determination as much as rendering it competitive to immunoassays. The reagent used for this, IPDOA-iodide, is by design not just enhancing the ionization yield of the peptide employed for GH quantification (T6), but also selectively modifying only cysteine containing peptides. This strongly reduces the fraction of matrix-derived-peptides being conjugated at the same time and, therefore, competes with IPDOA-T6 in the electrospray process. The work reported here is constituting the first application of peptide conjugation affording improved limits of detection for mass spectrometric quantification of proteins from native sera.
